16. Epidiolex

GW Pharma growing area for CBD Epidiolex
(GW Pharma)

Active ingredient: cannabidiol
Disease: Lennox-Gastaut syndrome and Dravet syndrome
Peak sales estimate: $1 billion
Approved: June 25
Company: GW Pharma

The scoop: With a nod for two rare forms of epilepsy, GW Pharma’s Epidiolex became the first cannabis-based prescription medicine in the U.S. The drug is a purified form of cannabidiol derived from plants that treats seizures associated with Lennox-Gastaut and Dravet syndromes, which tend to appear in childhood, have a higher mortality rate than other types of epilepsy and do not respond to many of the drugs typically used to treat epilepsy. While it is unclear how, exactly, Epidiolex wards off seizures, it doesn’t appear to interact with cannabinoid receptors and does not look to have abuse potential. Despite nabbing the FDA’s OK in June, GW Pharma couldn’t launch the drug until the Drug Enforcement Administration rescheduled Epidiolex, which it did in September. However, the rescheduling of cannabidiol—Epidiolex's active ingredient—is not a blanket decision. Cannabis and other forms of cannabidiol remain classified as Schedule I substances, a category that covers drugs with no therapeutic value and high potential for abuse. — Amirah Al Idrus

16. Epidiolex

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.